Increased risk of early virological failure in non-European HIV-1-infected patients in a Dutch cohort on highly active antiretroviral therapy

HIV Medicine

Volumn 6, Issue 5, 2005, Pages 299-306

  van den Berg, J B ^a   Hak, E ^a   Vervoort, S C J M ^a   Hoepelman, I M ^a   Boucher, C A B ^a   Schuurman, R ^a   Schneider, M M E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Adherence; Antiretroviral therapy; Epidemiology; HIV; Resistance; Resource poor; Subtype

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICA; ARTICLE; ASIAN; CENTRAL AMERICA; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DRUG BLOOD LEVEL; DRUG EXPOSURE; EUROPE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SIDE EFFECT; SOUTH AMERICA; TREATMENT FAILURE; VIROLOGY; VIRUS LOAD; VIRUS RESISTANCE;

ADULT; AFRICA; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; RETROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 25144458563     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00304.x     Document Type: Article

References (26)

1. Joint United Nations Program on HIV/AIDS (UNAIDS). AIDS Epidemic Update. http://www.unaids.org 2000.
2. Op de Coul E, van Valkengoed I, van Sighem A, de Wolf F, van de Laar M. HIV and AIDS in The Netherlands. RIVM Report 44110001, National Institute for Public Health and the Environment, Bilthoven, 2002.
3. Barry SM, Lloyd-Owen SJ, Madge SJ et al. The changing demographics of new HIV diagnoses at a London centre from 1994 to 2000. HIV Med 2002; 3: 129-134.
4. Frater AJ, Dunn DT, Beardall AJ et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 2002; 16: 1139-1146.
5. Holguin A, Alvarez A, Soriano V. High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid. AIDS 2002; 16: 1163-1170.
6. Miller LG, Liu H, Hays RD et al. Knowledge of antiretroviral regimen dosing and adherence: a longitudinal study. Clin Infect Dis 2003; 36: 514-518.
7. Dieleman JP, Sturkenboom MCJM, Jambroes M et al. Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate; the Athena cohort. Arch Intern Med 2002; 162: 1493-1501.
8. Dutch Association of HIV Doctors (NVAB). Antiretroviral Treatment in The Netherlands. Kwaliteitsinstituut voor de Gezondheidszorg CBO, van Zuiden, Alphen aan den Rijn, 2002.
9. National Center for Infectious Diseases Division of HIV/AIDS. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 1-19.
10. Ledergerber B, Egger M, Opravil M et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353: 863-868.
11. Tural C, Ruiz L, Holtzer C et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16: 209-218.
12. Johnsons VA, Brun-Vézinet F, Clotet B et al. Drug resistance mutations in HIV-1. Topics HIV Med 2003; 11: 215-221.
13. Hugen PW, Verweij-van Wissen CP, Burger DM, Wuis EW, Koopmans PP, Hekster YA. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999; 727: 139-149.
14. Moore AL, Kirk O, Johnson AM et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 2003; 32: 452-461.
15. Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-129.
16. Balslev U, Monforte AD, Stergiou G et al. Influence of age on rates of new AIDS-defining diseases and survival in 6546 AIDS patients. Scand J Infect Dis 1997; 29: 337-343.
17. Plana M, Martinez C, Garcia F et al. Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors. J Acquir Immune Defic Syndr 2002; 29: 429-434.
18. Frater AJ, Beardall A, Ariyoshi K et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS 2001; 15: 1493-1502.
19. Miller V, Mocroft A, Reiss P et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med 1999; 130: 570-577.
20. Burns FM, Fakoya AD, Copas AJ, French PD. Africans in London continue to present with advanced HIV disease in the era of highly active antiretroviral therapy. AIDS 2001; 15: 2453-2455.
21. Jensen-Fangel S, Pedersen L, Pedersen C et al. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis 2002; 35: 1541-1548.
22. Little SJ, Holte S, Routy JP et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-394.
23. de Wit S, Boulme R, Poll B, Clumeck N, Schmit JC, Van der Meeren O. Nelfinavir-containing regimen in treatment-naive HTV-1 patients: comparison of efficacy in B versus non-B subtypes. Sixth International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 2002 [Poster 195].
24. Ribaudo H, Clifford D, Gulick R et al. Relationships between efavirenz pharmacokinetics, side effects, drug discontinuation, virologic response, and race: results from ACTG A05095/A50975. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 132].
25. Haas D, Ribaudo H, Kin R et al. A common CYP2B6 variant is associated with efavirenz pharmacokinetics and central nervous system side effects: AACTG Study NWCS214. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 133].
26. Nieuwkerk PT, Sprangers AM, Burger DM et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 2001; 161: 1962-1968.